Skip to main content

Table 1 Demographic and baseline characteristics a

From: Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Characteristics, mean (SD)b

PBO (n = 332)

ACL400/FOR12 FDC (n = 335)

ACL400/FOR6 FDC (n = 333)

ACL 400 (n = 337)

FOR 12 (n = 332)

Age, years

63.5 (8.9)

64.2 (8.9)

63.9 (9.2)

64.4 (8.7)

63.7 (8.7)

Male, n (%)

175 (52.7)

168 (50.1)

187 (56.2)

188 (55.8)

169 (50.9)

White, n (%)

317 (95.5)

305 (91.0)

309 (92.8)

314 (93.2)

311 (93.7)

Current smoker, n (%)

169 (50.9)

173 (51.6)

176 (52.9)

171 (50.7)

171 (51.5)

Smoking history, pack-years

53.3 (28.5)

53.3 (27.2)

52.1 (25.8)

52.0 (26.1)

52.5 (23.7)

Prebronchodilator FEV1, L

1.35 (0.54)

1.34 (0.53)

1.40 (0.54)

1.34 (0.53)

1.37 (0.52)

Postbronchodilator FEV1, % of predicted

52.6 (13.3)

53.2 (13.4)

54.7 (12.9)

53.0 (13.3)

53.9 (13.1)

Bronchial reversibility, %

18.4 (15.2)

17.2 (14.6)

17.7 (15.0)

19.1 (16.5)

17.3 (14.7)

COPD severity, n (%)c

     

Moderate

177 (53.3)

189 (56.4)

203 (61.0)

184 (54.6)

197 (59.3)

Severe

150 (45.2)

142 (42.4)

127 (38.1)

147 (43.6)

131 (39.5)

Baseline efficacy variablesd

     

SGRQ total score

45.3 (17.9)

47.6 (16.9)

46.2 (17.9)

45.2 (17.8)

45.8 (17.9)

BDI focal score

6.4 (2.4)

6.2 (2.1)

6.5 (2.2)

6.5 (2.3)

6.3 (2.3)

Rescue medication use, puffs/day

4.2 (3.9)

4.5 (3.7)

4.0 (3.3)

4.0 (3.4)

4.3 (3.7)

EXACT-RS score

11.03 (5.84)

11.89 (6.51)

11.46 (6.25)

11.27 (6.33)

11.40 (6.57)

NiSCI score

0.95 (0.63)

1.10 (0.70)

0.99 (0.69)

1.00 (0.70)

0.99 (0.71)

EMSCI score

1.07 (0.58)

1.19 (0.63)

1.15 (0.64)

1.13 (0.65)

1.13 (0.66)

  1. aFor the safety population, unless indicated otherwise; bAll results reported as mean values with standard deviations, unless indicated otherwise; cCOPD severity based on GOLD 2011 update guidelines [32]. A small (<2%) portion of the population (not shown here) were diagnosed as having mild or very severe COPD at baseline; dFor the intention-to-treat population: PBO, n = 331; ACL400/FOR12 FDC, n = 335; ACL400/FOR6 FDC, n = 333; ACL 400, n = 337; FOR 12, n = 332; Total, N = 1669.
  2. ACL 400, aclidinium 400μg; ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400μg and formoterol 12μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400μg and formoterol 6μg; BDI, Baseline Dyspnea Index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FOR 12, formoterol 12μg; SGRQ, St. George’s Respiratory Questionnaire; PBO, placebo; SD, standard deviation.